Timothy Shapiro, MD
Interventional Cardiology · Wynnewood, PANPI 1285630566
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $88,660 of the $96,122 with a category attached, or 92.2%. AbbVie accounts for 70.1% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $20,252 and has fallen 82.2% since, to $3,604 in 2025. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $223.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$67K
- Astrazeneca UK Limited$19K
- Boehringer Ingelheim Pharma GmbH & Co.kg$2K
- Boston Scientific$2K
- Medtronic$1K
- Janssen Research & Development, LLC$934
- plus $3K from 26 others
Across 57 payments — averaging $2688.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$94K
- Philips North America LLC$44K
- Biotronik Inc.$5K
- Medtronic$4K
- Boston Scientific$3K
- AbbVie$3K
What the payments were for
- Consulting fees$88,66092%
- Travel & lodging$6241%
- Food & beverage$6,8297%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $67,363 |
| Astrazeneca UK Limited | 9 | $19,297 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $2,000 |
| Boston Scientific | 199 | $1,901 |
| Medtronic(2 entities) | 34 | $1,212 |
| Janssen Research & Development, LLC | 9 | $934 |
| AstraZeneca | 58 | $915 |
| Heartflow, Inc. | 7 | $382 |
| Novartis | 16 | $302 |
| Abiomed | 3 | $217 |
| Boehringer Ingelheim | 10 | $212 |
| Shockwave Medical, Inc | 8 | $205 |
| Novo Nordisk | 7 | $182 |
| Amgen | 7 | $139 |
| Pfizer | 9 | $128 |
| E.r. Squibb & Sons, L.L.C. | 7 | $120 |
| Penumbra, Inc. | 1 | $113 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $86 |
| Johnson & Johnson | 4 | $85 |
| Bayer | 3 | $48 |
| Acist Medical Systems, Inc. | 1 | $43 |
| Edwards Lifesciences | 1 | $38 |
| Terumo Medical Corporation | 2 | $34 |
| Livanova USA, Inc. | 1 | $29 |
| Cardiovascular Systems Inc. | 2 | $26 |
| Getinge USA Sales, LLC | 1 | $23 |
| Teleflex LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $15 |
| Biosense Webster, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $14 |
| Biotronik Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$20,675
- BREZTRI$17,670
- OFEV$2,000
- BREZTRI AEROSPHERE$1,627
- Resolute$478
- AVVIGO Guidance System$422
- FFRct$271
- FFRangio$165
- Impella$142
- COREVALVE EVOLUT R$139
- Indigo$113
How this compares
$96,122 in reported general payments places this provider in the 90th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 414 | $558,471 |
| Repatha SureclickEvolocumab | 211 | $220,892 |
| XareltoRivaroxaban | 161 | $177,270 |
| EntrestoSacubitril/Valsartan | 84 | $113,277 |
| FarxigaDapagliflozin Propanediol | 103 | $113,193 |
| JardianceEmpagliflozin | 64 | $75,822 |
| VascepaIcosapent Ethyl | 50 | $42,942 |
| Praluent PenAlirocumab | 40 | $39,721 |
| NexletolBempedoic Acid | 28 | $25,365 |
| BrilintaTicagrelor | 31 | $24,328 |
| Icosapent Ethyl | 48 | $18,874 |
| Rosuvastatin Calcium | 970 | $18,056 |
| Metoprolol Succinate | 926 | $17,023 |
| Ezetimibe | 556 | $16,519 |
| Atorvastatin Calcium | 970 | $12,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $128 | $558,471414 claims |
| Johnson & JohnsonXarelto | $85 | $177,270161 claims |
| AstraZenecaFarxiga, Brilinta | $915 | $137,521134 claims |
| NovartisEntresto | $302 | $113,27784 claims |
| Boehringer IngelheimJardiance | $212 | $75,82264 claims |
| Esperion Therapeutics, Inc.Nexletol | $15 | $25,36528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Wynnewood
- William GrayWynnewood$753K
- Eric GnallWynnewood$183K
- Hamza HafeezWynnewood$32K
- David BarryWynnewood$26K
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.